Success Story: Vaccine Development Expert Achieves EB-1B Approval After Successful RFE Response
Client’s Testimonial:
"It was really a wonderful experience working with you. The professionalism you guys showed is beyond any words, and I am truly happy with all the efforts.”
On March 9th, 2026, we received another EB-1B (Outstanding Professors and Researchers) Approval for a Research Associate in the Field of Vaccine Development (Approval Notice).
General Field: Vaccine Development
Position at the Time of Case Filing: Research Associate
Country of Origin: India
State of Residence at the Time of Filing: New York
Approval Notice Date: March 9th, 2026
Processing Time: 17 months and 2 days
Case Summary:
Drawing on our extensive experience and a proven track record of over 32,000 successful cases, our expert team secured an EB-1B approval for a research associate from India whose pioneering research in vaccine development, mucosal immunology, and pathogen detection advances critical capabilities in infectious disease prevention and national biosecurity.
Client Background and Expertise
With a Ph.D. and an M.Phil. in microbiology, the client specializes in recombinant vaccine design, mucosal immune responses, and molecular diagnostics for dangerous pathogens. The proposed endeavor focuses on developing outer membrane vesicles, investigating lung immunity mechanisms following vaccination, and addressing secondary bacterial infections arising from influenza, research at the direct intersection of public health preparedness and U.S. biosecurity.
Exceptional Credentials
The client’s qualifications include:
- 14 peer-reviewed journal articles (6 first-authored) and 2 first-authored abstracts
- 148 citations
- At least 21 peer reviews
“Thus, [Client]’s record of achievement to date more than evidences the indispensability of [Client]’s research to the U.S. or any other country.”
Approval After Successful RFE ResponseFollowing an RFE issued during adjudication, our expert team prepared a thorough and well-supported response addressing each point raised. The petition was ultimately approved in over 17 months. It has been an honor to support this journey, and we extend our sincere best wishes for the client’s continued success in advancing vaccine science and strengthening American leadership in infectious disease research.

